Xeljanz

What is Xeljanz?

Xeljanz is an oral Janus kinase (JAK) inhibitor used as a disease‑modifying therapy for several immune‑mediated inflammatory conditions. It is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC). By modulating the JAK‑STAT signaling pathway, Xeljanz reduces inflammation and immune system overactivity, thereby alleviating symptoms and preventing disease progression.

Reference: U.S. FDA Xeljanz Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688, NCT01375647, NCT01463232)

What are the other popular names for Xeljanz?

Xeljanz is the brand name for the active ingredient tofacitinib. In addition to Xeljanz, the extended‑release formulation is marketed as Xeljanz XR in some regions. The generic name, tofacitinib, is also used in scientific literature and clinical practice.

Reference: U.S. FDA; MedlinePlus

What is the drug classification of Xeljanz?

Xeljanz is classified as an oral Janus kinase (JAK) inhibitor. It falls under the therapeutic category of immunomodulatory agents and is used to modify the disease course in autoimmune conditions by targeting intracellular signaling pathways.

Reference: U.S. FDA; World Health Organization (WHO) guidelines on immunomodulatory therapies

What is the mode of action of Xeljanz?

Xeljanz works by inhibiting one or more of the Janus kinase enzymes (primarily JAK1 and JAK3, and to a lesser extent JAK2). This inhibition blocks the JAK‑STAT pathway, which is essential for the signaling of various pro‑inflammatory cytokines (such as interleukins and interferons). The result is a reduction in inflammatory activity and modulation of the immune response, leading to improved clinical outcomes in conditions like RA, PsA, and UC.

Reference: PubMed (e.g., O’Shea et al., 2013 on JAK inhibitors); U.S. FDA

What are the primary uses of Xeljanz?

Xeljanz is approved for the treatment of:

• Rheumatoid Arthritis (RA): To reduce joint inflammation, pain, and prevent joint damage in patients with moderate to severe RA who have had an inadequate response or intolerance to methotrexate.
• Psoriatic Arthritis (PsA): To improve signs and symptoms, physical function, and quality of life in patients with active PsA.
• Ulcerative Colitis (UC): To induce and maintain remission in adult patients with moderately to severely active UC.

Reference: U.S. FDA; ClinicalTrials.gov

What is the recommended dosage and administration for Xeljanz?

• For Rheumatoid Arthritis and Psoriatic Arthritis:
  • Xeljanz (Immediate-Release): Typically, 5 mg twice daily.
  • Xeljanz XR (Extended-Release): Generally, 11 mg once daily.
• For Ulcerative Colitis:
  • Induction Phase: 10 mg twice daily for the first 8 weeks.
  • Maintenance Phase: 5 mg twice daily thereafter.
• Administration:
  • Xeljanz is taken orally, with or without food. Consistent daily dosing at the same time is recommended to maintain therapeutic drug levels.

Reference: U.S. FDA Xeljanz Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688, NCT01463232)

What prescribing information is important for Xeljanz?

• Indications:
  • Xeljanz is indicated for adult patients with RA, PsA, or UC who have shown inadequate response or intolerance to conventional therapies (e.g., methotrexate for RA).
• Contraindications:
  • It is contraindicated in patients with severe infections, active tuberculosis, or known hypersensitivity to tofacitinib or any of its components.
• Monitoring:
  • Regular monitoring of complete blood counts, liver enzymes, lipid profiles, and assessment for signs of infection is recommended.
• Special Considerations:
  • Patients should be evaluated for latent tuberculosis before starting treatment.
  • Use with caution in patients with a history of cardiovascular disease and malignancy.

Reference: U.S. FDA; National Institutes of Health (NIH); American College of Rheumatology (ACR) guidelines

What safety information, side effects, warnings, and cautions are associated with Xeljanz?

• Common Side Effects:
  • Upper respiratory tract infections, headache, diarrhea, and nasopharyngitis.
• Serious Side Effects:
  • Increased risk of serious infections (including tuberculosis), blood clots, and certain malignancies.
• Warnings & Cautions:
  • Infections: There is an increased risk of opportunistic infections; patients should be screened for latent TB and monitored closely.
  • Thromboembolic Events: Use caution in patients with risk factors for venous thromboembolism.
  • Malignancy: Long-term immunosuppression may increase the risk of cancers, particularly lymphomas and skin cancers.
  • Cardiovascular Risk: Caution is advised in patients with a history of cardiovascular events.
  • Lipid Changes: Xeljanz may cause an increase in cholesterol levels; periodic lipid monitoring is recommended.
• Pregnancy and Lactation:
  • Xeljanz is not recommended during pregnancy or breastfeeding due to potential teratogenic effects and limited safety data.

Reference: U.S. FDA Xeljanz Prescribing Information; PubMed; ACR Guidelines

What drug interactions should be considered with Xeljanz?

• Immunosuppressants:
  • Concomitant use with other potent immunosuppressive agents (e.g., biologics) may increase the risk of infections.
• CYP3A4 Inhibitors:
  • Drugs such as ketoconazole or clarithromycin may increase the plasma concentration of tofacitinib, potentially enhancing adverse effects.
• Vaccines:
  • Live vaccines should generally be avoided during treatment with Xeljanz due to the risk of infection.
• Other Medications:
  • Always inform your healthcare provider of all concomitant medications (including over-the-counter drugs and supplements) to avoid potential interactions.

Reference: U.S. FDA; Clinical Pharmacology Reviews on PubMed

Frequently Asked Questions (FAQs)

Q: How quickly does Xeljanz begin to work?
A: Some patients may notice improvement in symptoms within 2–4 weeks, although maximum benefits may take longer to manifest.

Q: Can Xeljanz be used as a monotherapy?
A: For rheumatoid arthritis and psoriatic arthritis, Xeljanz is often used in patients with an inadequate response to conventional therapy, but it can be used as monotherapy or in combination with methotrexate. For ulcerative colitis, it is used in patients who have not responded adequately to conventional treatment.

Q: What precautions should I take regarding infections?
A: Patients should be screened for latent tuberculosis before starting Xeljanz and monitored for signs of infection during treatment. Contact your doctor immediately if you develop signs of infection.

Q: Is Xeljanz safe during pregnancy?
A: Xeljanz is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment.

Q: How should I manage missed doses?
A: If you miss a dose, take it as soon as you remember. If it is near the time of your next dose, skip the missed dose—do not double up.

Reference: U.S. FDA Xeljanz Prescribing Information; ACR Guidelines; ClinicalTrials.gov

Where can I find additional clinical evidence and detailed information about Xeljanz?

For more comprehensive data on Xeljanz’s efficacy, safety, and dosing, refer to:

• U.S. Food and Drug Administration (FDA) Website: FDA.gov
• ClinicalTrials.gov: (e.g., NCT01039688 for RA, NCT01375647 for PsA, NCT01463232 for UC)
• PubMed: For peer‑reviewed research articles on tofacitinib
• American College of Rheumatology (ACR) and National Institutes of Health (NIH) Guidelines

Reference: U.S. FDA; ClinicalTrials.gov; PubMed; ACR

Final Thoughts

Xeljanz (tofacitinib) is a powerful oral JAK inhibitor that offers effective symptom relief and disease modification for patients with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. By blocking key pathways in the immune response, Xeljanz reduces inflammation and improves clinical outcomes. However, its use is associated with an increased risk of infections, thromboembolic events, and potential malignancies, necessitating careful patient selection, thorough monitoring, and management of drug interactions. Always consult your healthcare provider to ensure Xeljanz is appropriate for your treatment plan.

Disclaimer: This guide is intended for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.